With a one year PEG ratio of 422.91, Alnylam Pharmaceuticals Inc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 92.01% of US stocks.
With a price/sales ratio of 45.85, Alnylam Pharmaceuticals Inc has a higher such ratio than 95.55% of stocks in our set.
Revenue growth over the past 12 months for Alnylam Pharmaceuticals Inc comes in at 241.39%, a number that bests 97.17% of the US stocks we're tracking.
If you're looking for stocks that are quantitatively similar to Alnylam Pharmaceuticals Inc, a group of peers worth examining would be GNTX, MXIM, FGEN, BMRN, and AMPH.
Arcutis receives a boost with positive seborrheic dermatitis study data Arcutis Biotherapeutics Inc. (ARQT) announced positive top line data from its seborrheic dermatitis study. This Phase 2 clinical trial seeks to assess the potential of ARQ-154 in treating seborrheic dermatitis. According to the data, Roflumilast foam 0.3% dispensed once daily...
Avisol Capital Partners on Seeking Alpha | October 2, 2020
DBMR has added a new report titled Antisense and RNAi therapeutics market with analysis provides the insights which bring marketplace clearly into the focus and thus help organizations make better decisions. The data and the information regarding the industry are
DBMR has added a new report titled Global Antisense and RNAi Therapeutics Market with analysis provides the insights which bring marketplace clearly into the focus and thus help organizations make better decisions. The data and the information regarding the industry are taken
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today positive topline results from the ILLUMINATE-B pediatric Phase 3 study of lumasiran, an investigational RNAi therapeutic targeting hydroxyacid oxidase 1 (HAO1) – the gene encoding glycolate oxidase (GO) – in development for the treatment of primary hyperoxaluria type 1 (PH1). ILLUMINATE-B is now the seventh Phase 3 study of an RNAi therapeutic that has yielded
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, will host an “RNAi Roundtable” webinar today at 12:00 p.m. ET, which will focus on progress across its ATTR amyloidosis programs. The Company will discuss the potential for a biannual subcutaneous dosing regimen for vutrisiran, as well as discuss ongoing Phase 3 development for patisiran and vutrisiran across the APOLLO-B, HELIOS-A, and HELIOS-B studies. The Company also annou